rs137852275
Variant summary
Our verdict is Pathogenic. The variant received 13 ACMG points: 13P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Moderate
The NM_000133.4(F9):c.1070G>A(p.Gly357Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G357R) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000133.4 missense
Scores
Clinical Significance
Conservation
Publications
- hemophilia BInheritance: XL Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen
- mild hemophilia BInheritance: XL Classification: SUPPORTIVE Submitted by: Orphanet
- moderately severe hemophilia BInheritance: XL Classification: SUPPORTIVE Submitted by: Orphanet
- severe hemophilia BInheritance: XL Classification: SUPPORTIVE Submitted by: Orphanet
- symptomatic form of hemophilia B in female carriersInheritance: XL Classification: SUPPORTIVE Submitted by: Orphanet
- thrombophilia, X-linked, due to factor 9 defectInheritance: XL Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 13 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| F9 | NM_000133.4 | c.1070G>A | p.Gly357Glu | missense_variant | Exon 8 of 8 | ENST00000218099.7 | NP_000124.1 | |
| F9 | NM_001313913.2 | c.956G>A | p.Gly319Glu | missense_variant | Exon 7 of 7 | NP_001300842.1 | ||
| F9 | XM_005262397.5 | c.941G>A | p.Gly314Glu | missense_variant | Exon 7 of 7 | XP_005262454.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| F9 | ENST00000218099.7 | c.1070G>A | p.Gly357Glu | missense_variant | Exon 8 of 8 | 1 | NM_000133.4 | ENSP00000218099.2 | ||
| F9 | ENST00000394090.2 | c.956G>A | p.Gly319Glu | missense_variant | Exon 7 of 7 | 1 | ENSP00000377650.2 | |||
| F9 | ENST00000643157.1 | n.1723+14G>A | intron_variant | Intron 6 of 6 |
Frequencies
GnomAD3 genomes Cov.: 22
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 22
ClinVar
Submissions by phenotype
Hereditary factor IX deficiency disease Pathogenic:1
- -
not provided Pathogenic:1
The F9 c.1070G>A; p.Gly357Glu variant (rs137852275), also known as 31053G>A, p.Gly311Glu or factor IX Amagasaki, is reported in the literature in multiple individuals affected with moderate to severe hemophilia A (Chavali 2009, Giannelli 1994, Hamasaki-Katagiri 2012, see link to FIX database and references therein). This variant is reported in ClinVar (Variation ID: 10647), and is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. The glycine at codon 357 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Functional assays show a complete loss of coagulant and esterase activities (Miyata 1991). Additionally, other amino acid substitutions at this codon (c.1069G>A; p.Gly357Arg, c.1070G>T; p.Gly357Val) have been reported in individuals with hemophilia B and are considered pathogenic (Chavali 2009, Giannelli 1994, Hamasaki-Katagiri 2012, FIX database and references therein). Based on available information, this variant is considered to be pathogenic. References: Link to FIX database: http://www.factorix.org Chavali S et al. Hemophilia B is a quasi-quantitative condition with certain mutations showing phenotypic plasticity. Genomics. 2009 Dec;94(6):433-7. Giannelli F et al. Haemophilia B: database of point mutations and short additions and deletions, fifth edition, 1994. Nucleic Acids Res. 1994 Sep;22(17):3534-46. Hamasaki-Katagiri N et al. Analysis of F9 point mutations and their correlation to severity of haemophilia B disease. Haemophilia. 2012 Nov;18(6):933-40. Miyata T et al. Factor IX Amagasaki: a new mutation in the catalytic domain resulting in the loss of both coagulant and esterase activities. Biochemistry. 1991 Nov 26;30(47):11286-91. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at